Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy

Valery Radchenko; Alfred Morgenstern; Amir R Jalilian; Caterina F Ramogida; Cathy Cutler; Charlotte Duchemin; Cornelia Hoehr; Ferrid Haddad; Frank Bruchertseifer; Haavar Gausemel; Hua Yang; Joao Alberto Osso; Kohshin Washiyama; Kenneth Czerwinski; Kirsten Leufgen; Marek Pruszyński; Olga Valzdorf; Patrick Causey; Paul Schaffer; Randy Perron; Samsonov Maxim; D Scott Wilbur; Thierry Stora; Yawen Li

doi:10.2967/jnumed.120.261016

Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy

J Nucl Med. 2021 Nov;62(11):1495-1503. doi: 10.2967/jnumed.120.261016. Epub 2021 Jul 22.

Authors

Valery Radchenko^{1

2}, Alfred Morgenstern³, Amir R Jalilian⁴, Caterina F Ramogida^{5

6}, Cathy Cutler⁷, Charlotte Duchemin^{8

9}, Cornelia Hoehr⁵, Ferrid Haddad¹⁰, Frank Bruchertseifer³, Haavar Gausemel¹¹, Hua Yang⁵, Joao Alberto Osso⁴, Kohshin Washiyama¹², Kenneth Czerwinski¹³, Kirsten Leufgen¹⁴, Marek Pruszyński^{15

16}, Olga Valzdorf¹⁷, Patrick Causey¹⁸, Paul Schaffer⁵, Randy Perron¹⁹, Samsonov Maxim²⁰, D Scott Wilbur²¹, Thierry Stora⁸, Yawen Li²¹

Affiliations

¹ Life Sciences Division, TRIUMF, Vancouver, British Columbia, Canada; [email protected].
² Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada.
³ European Commission, Joint Research Centre, Karlsruhe, Germany.
⁴ International Atomic Energy Agency, Vienna, Austria.
⁵ Life Sciences Division, TRIUMF, Vancouver, British Columbia, Canada.
⁶ Simon Fraser University, Burnaby, British Columbia, Canada.
⁷ Collider Accelerator Department, Brookhaven National Laboratory, Upton, New York.
⁸ CERN, Geneva, Switzerland.
⁹ Institute for Nuclear and Radiation Physics, KU Leuven, Heverlee, Belgium.
¹⁰ Arronax, Nantes, France.
¹¹ Bayer American Samoa, Oslo, Norway.
¹² Advanced Clinical Research Center, Fukushima Medical University, Fukushima, Japan.
¹³ Radiochemistry Program, Department of Chemistry, University of Nevada, Las Vegas, Nevada.
¹⁴ SCIPROM Sarl, Saint-Sulpice, Switzerland.
¹⁵ Institute of Nuclear Chemistry and Technology, Warsaw, Poland.
¹⁶ NOMATEN Centre of Excellence, National Centre for Nuclear Research, Otwock, Poland.
¹⁷ Isotope JSC, Rosatom State Corp., Moscow, Russian Federation.
¹⁸ BWXT Medical Ltd., Ottawa, Ontario, Canada.
¹⁹ Canadian Nuclear Laboratories, Chalk River, Ontario, Canada.
²⁰ State Scientific Centre of the Russian Federation, Leypunsky Institute for Physics and Power Engineering, Rosatom State Corp., Obninsk, Russian Federation; and.
²¹ Department of Radiation Oncology, University of Washington, Seattle, Washington.

Abstract

Encouraging results from targeted α-therapy have received significant attention from academia and industry. However, the limited availability of suitable radionuclides has hampered widespread translation and application. In the present review, we discuss the most promising candidates for clinical application and the state of the art of their production and supply. In this review, along with 2 forthcoming reviews on chelation and clinical application of α-emitting radionuclides, The Journal of Nuclear Medicine will provide a comprehensive assessment of the field.

Keywords: 211At; 212Pb/212Bi; 225Ac/213Bi; 227Th/223Ra; production and supply of radionuclides; targeted α-therapy.

Publication types

Review

MeSH terms

Alpha Particles* / therapeutic use
Humans
Radioisotopes* / chemistry
Radioisotopes* / therapeutic use
Radiopharmaceuticals / therapeutic use

Substances

Radioisotopes
Radiopharmaceuticals